Dysbetalipoproteinemia is associated with increased risk of coronary and peripheral vascular disease.

We demonstrated the risks of ASCVD and PVD in DBL are >3-fold and >13-fold higher, respectively, as compared to normolipidemic controls. Furthermore, the risk of PVD is ∼4-fold higher in DBL than in FH. Adequate screening of DBL is imperative to improve the clinical care of these patients by preventing the development of atherosclerotic cardiovascular disease.